Tactical Therapeutics, Inc
Monday, February 26, 2024
Uris
Oncology
Tactical Therapeutics, Inc is a clinical stage private Co in New York, developing Carboxyamidotriazole orotate (CTO) which has shown safety and efficacy in primary brain cancer and many undruggable heavily pretreated solid cancers with resistant mutations.
CTO has unique properties which allow it to succeed, e.g.,
- Inhibits calcium signals linked to several oncogenes, and calcium channels (multi-targeted).
- Inhibits inflammatory cytokines and a perfect companion for Immunotherapies to reverse redundancy
-Targets multiple cell types, and multiple genomic markers, leaving the tumor without options.
- Crosses the Blood Brian Barrier.
Completed three Phase 1 trials in i) Forty-four Advanced Cancer Patients with different solid refractory tumors and ii) Forty-two GBM patients- 27 Recurrent and 15 Newly diagnosed.
Plan to run randomized Fast Track Orphan Drug Phase 2 in Recurrent GBM, followed by and Phase 2 trials in other solid cancers. (RCC, CRC, NSCLC, OC)
State
NY
Country
United States
Website
https://tacticaltherapeutics.com
CEO/Top Company Official
Rashida A. Karmali, JD, Ph. D, MBA
Lead Product in Development
Carboxyamidotriazole Orotate (CTO
Development Phase of Primary Product
Phase II
Number Of Unlicensed Products
One (1)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}